Table 1.
Clinical research on IDO-targeted therapies in ovarian cancer.
| Trial name | NCT # | Study synopsis |
|---|---|---|
| How our immune system can help fight cancer | Tregs are immunosuppressive and promote cancer progression by inhibiting the anti-tumor immune response. In most T cell populations tryptophan depletion leads to decreased activity and viability, but Tregs are less susceptible to tryptophan depletion than other T cell populations. We hypothesize that genetic polymorphisms within IDO alter enzymatic activity within Treg populations and affect patient outcomes. This study will examine IDO polymorphisms in EOC tumors and ascites. | |
| Epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer | Epacadostat is an IDO1 inhibitor that may reduce tumor cell growth. This study will examine how neoadjuvant treatment with epacadostat affects disease progression (and adverse reactions) in newly diagnosed stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancers. | |
| DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 in treating patients with ovarian, fallopian tube, or primary peritoneal cancer in remission | Antigens, such as the cancer-specific antigen NY-ESO-1 protein, are found on many cancer cells and assist the immune system in targeting and destroying cancer cells. Some tumors, however, express IDO which promotes tumor growth and progression by suppressing the immune system. This study will determine the side effects, best dose and initial effectiveness of combining the IDO inhibitor INCB024360 with a cancer vaccine (DEC-205/NY-ESO-1 fusion protein CDX-1401) and an immune stimulant (poly ICLC). The goal is to generate a stronger, longer lasting anti-tumor immune response in patients with ovarian, fallopian tube and primary peritoneal cancers in remission. | |
| Study of DPX-Survivac vaccine therapy and epacadostat in patients with recurrent ovarian cancer | This study will determine the safety and immunomodulatory effects of combining the IDO1 inhibitor epacadostat with the immunotherapeutic vaccine DPX-Survivac and cyclophosphamide chemotherapy in patients with recurrent ovarian, fallopian tube or peritoneal cancers. | |
| A phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only EOC, PPC or FTC following complete remission with first-line chemotherapy | This randomized study will examine the effectiveness of the IDO inhibitor INCB024360 compared to tamoxifen in biochemical recurrent ovarian cancer patients following complete remission with first-line chemotherapy. | |
| Intraperitoneal natural killer cells and INCB024360 for recurrent ovarian, fallopian tube, and primary peritoneal cancer | This study will determine the maximum tolerated dose of the IDO inhibitor INCB024360 when administered as part of a larger regimen of haploidentical donor NK cells and IL-2 following a non-myeloablative cyclophosphamide/fludarabine chemotherapy regimen in recurrent ovarian, fallopian tube and primary peritoneal cancers. | |
| Safety and efficacy of CRS-207 with epacadostat in platinum-resistant ovarian, fallopian or peritoneal cancer (SEASCAPE) | This study will determine the safety and potential efficacy of the investigational cancer drugs CRS-207 (an immune stimulant), epacadostat (an IDO1 inhibitor) and pembrolizumab (anti-PD-1 immunotherapy) in patients with platinum-resistant ovarian, fallopian tube or peritoneal cancers. | |
| Pembrolizumab and epacadostat treating participants with recurrent, persistent or progressive ovarian clear cell carcinoma | This phase II trial will determine the effectiveness of the combination of pembrolizumab and epocadostat in treating patients with ovarian clear cell carcinoma. |
EOC, epithelial ovarian carcinoma; FTC, fallopian tube cancer; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; NK, natural killer; PD-1, programmed cell death protein-1; PPC, primary peritoneal cancer; Tregs, regulatory CD4 T cells.